Last reviewed · How we verify
ARN-75039 oral capsules
At a glance
| Generic name | ARN-75039 oral capsules |
|---|---|
| Also known as | SAD: Cohorts 1 through 5 MAD: Cohorts 7 through 9 |
| Sponsor | Arisan Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects (PHASE1)
- A Comparison of the Pharmacokinetic Properties of ARN-75039 Tablets With Excipients to Neat ARN-75039 in Hydroxypropyl Methylcellulose (HPMC) Capsules in Healthy Adult Participants Under Fed Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARN-75039 oral capsules CI brief — competitive landscape report
- ARN-75039 oral capsules updates RSS · CI watch RSS
- Arisan Therapeutics, Inc. portfolio CI